{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T19:23:17Z","timestamp":1787426597732,"version":"build-2736575974"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40273-026-01622-3","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T11:55:01Z","timestamp":1780574101000},"page":"1109-1124","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Informing the Equitable Implementation of Hepatitis C Interventions: Cost-Effectiveness Modeling in Rural Populations of People Who Inject Drugs"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5787-6275","authenticated-orcid":false,"given":"Sheri A.","family":"Tubach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois M.","family":"Castonguay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"1622_CR1","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1097\/HEP.0000000000000927","volume":"81","author":"EW Hall","year":"2025","unstructured":"Hall EW, Bradley H, Barker LK, Lewis KC, Shealey J, Valverde E, et al. Estimating Hepatitis C prevalence in the United States, 2017\u20132020. Hepatology. 2025;81:625\u201336. https:\/\/doi.org\/10.1097\/HEP.0000000000000927.","journal-title":"Hepatology"},{"key":"1622_CR2","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ebiom.2018.10.007","volume":"37","author":"S Ramachandran","year":"2018","unstructured":"Ramachandran S, Thai H, Forbi JC, Galang RR, Dimitrova Z, Xia G, et al. A large HCV transmission network enabled a fast-growing HIV outbreak in rural Indiana, 2015. EBioMedicine. 2018;37:374\u201381. https:\/\/doi.org\/10.1016\/j.ebiom.2018.10.007.","journal-title":"EBioMedicine"},{"key":"1622_CR3","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.2147\/IDR.S403133","volume":"16","author":"SB Woyesa","year":"2023","unstructured":"Woyesa SB, Amente KD. Hepatitis C virus dynamic transmission models among people who inject drugs. Infect Drug Resist. 2023;16:1061\u20138. https:\/\/doi.org\/10.2147\/IDR.S403133.","journal-title":"Infect Drug Resist"},{"key":"1622_CR4","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1093\/infdis\/jis677","volume":"207","author":"J Doerrbecker","year":"2013","unstructured":"Doerrbecker J, Behrendt P, Mateu-Gelabert P, Ciesek S, Riebesehl N, Wilhelm C, et al. Transmission of Hepatitis C virus among people who inject drugs: viral stability and association with drug preparation equipment. J Infect Dis. 2013;207:281\u20137. https:\/\/doi.org\/10.1093\/infdis\/jis677.","journal-title":"J Infect Dis"},{"key":"1622_CR5","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/QAI.0000000000001098","volume":"73","author":"MM Van Handel","year":"2016","unstructured":"Van Handel MM, Rose CE, Hallisey EJ, Kolling JL, Zibbell JE, Lewis B, et al. County-level vulnerability assessment for rapid dissemination of HIV or HCV infections among persons who inject drugs, United States. JAIDS J Acquir Immune Defic Syndr. 2016;73:323\u201331. https:\/\/doi.org\/10.1097\/QAI.0000000000001098.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"1622_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.drugalcdep.2018.08.029","volume":"193","author":"MS Ellis","year":"2018","unstructured":"Ellis MS, Kasper ZA, Cicero TJ. Twin epidemics: the surging rise of methamphetamine use in chronic opioid users. Drug Alcohol Depend. 2018;193:14\u201320. https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.08.029.","journal-title":"Drug Alcohol Depend"},{"key":"1622_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-023-16017-8","volume":"23","author":"CR Balsom","year":"2023","unstructured":"Balsom CR, Farrell A, Kelly DV. Barriers and enablers to testing for Hepatitis C virus infection in people who inject drugs\u2014a scoping review of the qualitative evidence. BMC Public Health. 2023;23:1038. https:\/\/doi.org\/10.1186\/s12889-023-16017-8.","journal-title":"BMC Public Health"},{"key":"1622_CR8","doi-asserted-by":"publisher","unstructured":"Platt L, Reed J, Minozzi S, Vickerman P, Hagan H, French C, et al. Effectiveness of needle\/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs - Platt, L - 2016 | Cochrane Library. [cited 2025 Aug 8]; https:\/\/doi.org\/10.1002\/14651858.CD012021\/full. Accessed 8 Aug 2025.","DOI":"10.1002\/14651858.CD012021\/full"},{"key":"1622_CR9","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S2468-1253(22)00346-6","volume":"8","author":"A Trickey","year":"2023","unstructured":"Trickey A, Fajardo E, Alemu D, Artenie AA, Easterbrook P. Impact of Hepatitis C virus point-of-care RNA viral load testing compared with laboratory-based testing on uptake of RNA testing and treatment, and turnaround times: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8:253\u201370. https:\/\/doi.org\/10.1016\/S2468-1253(22)00346-6.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1622_CR10","doi-asserted-by":"publisher","unstructured":"Bhattacharya D, Aronsohn A, Price J, Lo Re V, the American Association for the Study of Liver Diseases\u2013Infectious Diseases Society of America HCV Guidance Panel, Heald J, et al. Hepatitis C Guidance 2023 Update: American Association for the study of liver diseases-infectious diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin Infect Dis. 2023. https:\/\/doi.org\/10.1093\/cid\/ciad319","DOI":"10.1093\/cid\/ciad319"},{"key":"1622_CR11","unstructured":"Global Health Sector Strategies On, Respectively, HIV, Viral Hepatitis and Sexually Transmitted Infections for the Period 2022-2030. [Internet]. World Health Organization; 2022 July. https:\/\/iris.who.int\/bitstream\/handle\/10665\/360348\/9789240053779-eng.pdf. Accessed 8 Aug 2025"},{"key":"1622_CR12","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/jrh.12307","volume":"35","author":"CHA Andrilla","year":"2019","unstructured":"Andrilla CHA, Moore TE, Patterson DG, Larson EH. Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: a 5\u2010year update. J Rural Health. 2019;35:108\u201312. https:\/\/doi.org\/10.1111\/jrh.12307.","journal-title":"J Rural Health"},{"key":"1622_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/jrh.70072","volume":"41","author":"NA Dockery","year":"2025","unstructured":"Dockery NA, Huang Q, Balio CP. An analysis of syringe service programs across the rural\u2010urban continuum in the United States. J Rural Health. 2025;41:e70072. https:\/\/doi.org\/10.1111\/jrh.70072.","journal-title":"J Rural Health"},{"key":"1622_CR14","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1111\/j.1360-0443.2012.03932.x","volume":"107","author":"P Vickerman","year":"2012","unstructured":"Vickerman P, Martin N, Turner K, Hickman M. Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in Hepatitis C Virus prevalence? Model projections for different epidemic settings. Addiction. 2012;107:1984\u201395. https:\/\/doi.org\/10.1111\/j.1360-0443.2012.03932.x.","journal-title":"Addiction"},{"key":"1622_CR15","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1093\/cid\/cit296","volume":"57","author":"NK Martin","year":"2013","unstructured":"Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis. 2013;57:S39-45. https:\/\/doi.org\/10.1093\/cid\/cit296.","journal-title":"Clin Infect Dis"},{"key":"1622_CR16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/add.13948","volume":"113","author":"H Fraser","year":"2018","unstructured":"Fraser H, Zibbell J, Hoerger T, Hariri S, Vellozzi C, Martin NK, et al. Scaling\u2010up HCV prevention and treatment interventions in rural United States\u2014model projections for tackling an increasing epidemic. Addiction. 2018;113:173\u201382. https:\/\/doi.org\/10.1111\/add.13948.","journal-title":"Addiction"},{"key":"1622_CR17","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1111\/add.14267","volume":"113","author":"H Fraser","year":"2018","unstructured":"Fraser H, Mukandavire C, Martin NK, Goldberg D, Palmateer N, Munro A, et al. Modelling the impact of a national scale\u2010up of interventions on Hepatitis C Virus transmission among people who inject drugs in Scotland. Addiction. 2018;113:2118\u201331. https:\/\/doi.org\/10.1111\/add.14267.","journal-title":"Addiction"},{"key":"1622_CR18","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1002\/hep.26431","volume":"58","author":"NK Martin","year":"2013","unstructured":"Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, et al. Hepatitis C Virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology. 2013;58:1598\u2013609. https:\/\/doi.org\/10.1002\/hep.26431.","journal-title":"Hepatology"},{"key":"1622_CR19","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1111\/jvh.12975","volume":"25","author":"N Scott","year":"2018","unstructured":"Scott N, Sacks\u2010Davis R, Pedrana A, Doyle J, Thompson A, Hellard M. Eliminating Hepatitis C: the importance of frequent testing of people who inject drugs in high\u2010prevalence settings. J Viral Hepat. 2018;25:1472\u201380. https:\/\/doi.org\/10.1111\/jvh.12975.","journal-title":"J Viral Hepat"},{"key":"1622_CR20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.drugpo.2017.07.006","volume":"47","author":"N Scott","year":"2017","unstructured":"Scott N, Doyle JS, Wilson DP, Wade A, Howell J, Pedrana A, et al. Reaching Hepatitis C virus elimination targets requires health system interventions to enhance the care cascade. Int J Drug Policy. 2017;47:107\u201316. https:\/\/doi.org\/10.1016\/j.drugpo.2017.07.006.","journal-title":"Int J Drug Policy"},{"key":"1622_CR21","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1111\/add.15456","volume":"116","author":"LK Marquez","year":"2021","unstructured":"Marquez LK, Fleiz C, Burgos JL, Cepeda JA, McIntosh C, Garfein RS, et al. Cost\u2010effectiveness of Hepatitis C virus (HCV) elimination strategies among people who inject drugs (PWID) in Tijuana, Mexico. Addiction. 2021;116:2734\u201345. https:\/\/doi.org\/10.1111\/add.15456.","journal-title":"Addiction"},{"key":"1622_CR22","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1111\/add.14731","volume":"114","author":"C Barbosa","year":"2019","unstructured":"Barbosa C, Fraser H, Hoerger TJ, Leib A, Havens JR, Young A, et al. Cost\u2010effectiveness of scaling\u2010up HCV prevention and treatment in the United States for people who inject drugs. Addiction. 2019;114:2267\u201378. https:\/\/doi.org\/10.1111\/add.14731.","journal-title":"Addiction"},{"key":"1622_CR23","doi-asserted-by":"publisher","first-page":"95","DOI":"10.17161\/kjm.vol1414597","volume":"14","author":"H Berland","year":"2021","unstructured":"Berland H, Hughes D. Is rural Kansas prepared? An assessment of resources related to the COVID-19 pandemic: Kansas COVID-19 resources. Kans J Med. 2021;14:95\u2013102. https:\/\/doi.org\/10.17161\/kjm.vol1414597.","journal-title":"Kans J Med"},{"key":"1622_CR24","unstructured":"CDC. NCHS Urban-Rural Classification Scheme for Counties [Internet]. Natl. Cent. Health Stat. 2025 [cited 2025 Aug 26]. https:\/\/www.cdc.gov\/nchs\/data-analysis-tools\/urban-rural.html. Accessed 26 Aug 2025"},{"key":"1622_CR25","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s40273-019-00864-8","volume":"38","author":"TJ Mattingly","year":"2020","unstructured":"Mattingly TJ, Slejko JF, Onukwugha E, Perfetto EM, Kottilil S, Mullins CD. Value in Hepatitis C virus treatment: a patient-centered cost-effectiveness analysis. Pharmacoeconomics. 2020;38:233\u201342. https:\/\/doi.org\/10.1007\/s40273-019-00864-8.","journal-title":"Pharmacoeconomics"},{"key":"1622_CR26","doi-asserted-by":"publisher","first-page":"879","DOI":"10.18553\/jmcp.2020.26.7.879","volume":"26","author":"TJ Mattingly","year":"2020","unstructured":"Mattingly TJ, Love BL. Changes in cost-effectiveness for chronic Hepatitis C virus pharmacotherapy: the case for continuous cost-effectiveness analyses. J Manag Care Spec Pharm. 2020;26:879\u201386. https:\/\/doi.org\/10.18553\/jmcp.2020.26.7.879.","journal-title":"J Manag Care Spec Pharm"},{"key":"1622_CR27","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2015","unstructured":"Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Fourth. Oxford University Press; 2015.","edition":"Fourth"},{"key":"1622_CR28","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1002\/hep.28497","volume":"63","author":"NK Martin","year":"2016","unstructured":"Martin NK, Vickerman P, Brew IF, Williamson J, Miners A, Irving WL, et al. Is increased Hepatitis C virus case\u2010finding combined with current or 8\u2010week to 12\u2010week direct\u2010acting antiviral therapy cost\u2010effective in UK prisons? A prevention benefit analysis. Hepatology. 2016;63:1796\u2013808. https:\/\/doi.org\/10.1002\/hep.28497.","journal-title":"Hepatology"},{"key":"1622_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae107","volume":"11","author":"LA Gonzalez Corro","year":"2024","unstructured":"Gonzalez Corro LA, Zook K, Landry M, Rosecrans A, Harris R, Gaskin D, et al. An analysis of social determinants of health and their implications for Hepatitis C Virus treatment in people who inject drugs: the case of Baltimore. Open Forum Infect Dis. 2024;11:ofae107. https:\/\/doi.org\/10.1093\/ofid\/ofae107.","journal-title":"Open Forum Infect Dis"},{"key":"1622_CR30","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.20.1.22146","volume":"20","author":"J Grebely","year":"2017","unstructured":"Grebely J, Dore GJ, Morin S, Rockstroh JK, Klein MB. Elimination of HCV as a public health concern among people who inject drugs by 2030\u2014what will it take to get there? J Int AIDS Soc. 2017;20:22146. https:\/\/doi.org\/10.7448\/IAS.20.1.22146.","journal-title":"J Int AIDS Soc"},{"key":"1622_CR31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jsat.2019.01.021","volume":"100","author":"O Falade-Nwulia","year":"2019","unstructured":"Falade-Nwulia O, Irvin R, Merkow A, Sulkowski M, Niculescu A, Olsen Y, et al. Barriers and facilitators of Hepatitis C treatment uptake among people who inject drugs enrolled in opioid treatment programs in Baltimore. J Subst Abuse Treat. 2019;100:45\u201351. https:\/\/doi.org\/10.1016\/j.jsat.2019.01.021.","journal-title":"J Subst Abuse Treat"},{"key":"1622_CR32","doi-asserted-by":"publisher","first-page":"S129","DOI":"10.1093\/cid\/cit302","volume":"57","author":"G Robaeys","year":"2013","unstructured":"Robaeys G, Grebely J, Mauss S, Bruggmann P, Moussalli J, De Gottardi A, et al. Recommendations for the management of Hepatitis C Virus Infection among people who inject drugs. Clin Infect Dis. 2013;57:S129-37. https:\/\/doi.org\/10.1093\/cid\/cit302.","journal-title":"Clin Infect Dis"},{"key":"1622_CR33","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa1702417","volume":"378","author":"S Zeuzem","year":"2018","unstructured":"Zeuzem S, Foster GR, Wang S, Asatryan A, Gane E, Feld JJ, et al. Glecaprevir-Pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med. 2018;378:354\u201369. https:\/\/doi.org\/10.1056\/NEJMoa1702417.","journal-title":"N Engl J Med"},{"key":"1622_CR34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jhep.2019.02.018","volume":"71","author":"J Mac\u00edas","year":"2019","unstructured":"Mac\u00edas J, Morano LE, T\u00e9llez F, Granados R, Rivero-Ju\u00e1rez A, Palacios R, et al. Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy. J Hepatol. 2019;71:45\u201351. https:\/\/doi.org\/10.1016\/j.jhep.2019.02.018.","journal-title":"J Hepatol"},{"key":"1622_CR35","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.14309\/ajg.0000000000000248","volume":"114","author":"B Pearlman","year":"2019","unstructured":"Pearlman B, Perrys M, Hinds A. Sofosbuvir\/Velpatasvir\/Voxilaprevir for previous treatment failures with Glecaprevir\/Pibrentasvir in chronic Hepatitis C infection. Am J Gastroenterol. 2019;114:1550\u20132. https:\/\/doi.org\/10.14309\/ajg.0000000000000248.","journal-title":"Am J Gastroenterol"},{"key":"1622_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2022.107589","volume":"139","author":"C Baxley","year":"2023","unstructured":"Baxley C, Borsari B, Reavis JV, Manuel JK, Herbst E, Becker W, et al. Effects of buprenorphine on opioid craving in comparison to other medications for opioid use disorder: a systematic review of randomized controlled trials. Addict Behav. 2023;139:107589. https:\/\/doi.org\/10.1016\/j.addbeh.2022.107589.","journal-title":"Addict Behav"},{"key":"1622_CR37","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.15585\/mmwr.mm6933a2","volume":"69","author":"BH Lambdin","year":"2020","unstructured":"Lambdin BH, Bluthenthal RN, Wenger LD, Wheeler E, Garner B, Lakosky P, et al. Overdose education and naloxone distribution within syringe service programs\u2014United States, 2019. MMWR Morb Mortal Wkly Rep. 2020;69:1117\u201321. https:\/\/doi.org\/10.15585\/mmwr.mm6933a2.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1622_CR38","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/21505594.2015.1085151","volume":"7","author":"N Scott","year":"2016","unstructured":"Scott N, Hellard M, McBryde ES. Modeling Hepatitis C virus transmission among people who inject drugs: assumptions, limitations and future challenges. Virulence. 2016;7:201\u20138. https:\/\/doi.org\/10.1080\/21505594.2015.1085151.","journal-title":"Virulence"},{"key":"1622_CR39","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jtbi.2018.11.013","volume":"481","author":"AB Pitcher","year":"2019","unstructured":"Pitcher AB, Borquez A, Skaathun B, Martin NK. Mathematical modeling of Hepatitis C virus (HCV) prevention among people who inject drugs: a review of the literature and insights for elimination strategies. J Theor Biol. 2019;481:194\u2013201. https:\/\/doi.org\/10.1016\/j.jtbi.2018.11.013.","journal-title":"J Theor Biol"},{"key":"1622_CR40","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1111\/add.14217","volume":"113","author":"Z Ward","year":"2018","unstructured":"Ward Z, Platt L, Sweeney S, Hope VD, Maher L, Hutchinson S, et al. Impact of current and scaled\u2010up levels of Hepatitis C prevention and treatment interventions for people who inject drugs in three UK settings\u2014what is required to achieve the WHO\u2019s HCV elimination targets? Addiction. 2018;113:1727\u201338. https:\/\/doi.org\/10.1111\/add.14217.","journal-title":"Addiction"},{"key":"1622_CR41","unstructured":"Provider Interactive Tools [Internet]. [cited 2025 Aug 8]. https:\/\/portal.kmap-state-ks.us\/PublicPage\/ProviderPricing\/ProviderInteractiveTools. Accessed 8 Aug 2025"},{"key":"1622_CR42","unstructured":"NDC List \u2013 The Web\u2019s Free National Drug Codes Reference Site [Internet]. [cited 2025 Aug 8]. https:\/\/ndclist.com\/. Accessed 8 Aug 2025"},{"key":"1622_CR43","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1093\/cid\/civ220","volume":"61","author":"DB Rein","year":"2015","unstructured":"Rein DB, Wittenborn JS, Smith BD, Liffmann DK, Ward JW. The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for Hepatitis C Virus. Clin Infect Dis. 2015;61:157\u201368. https:\/\/doi.org\/10.1093\/cid\/civ220.","journal-title":"Clin Infect Dis"},{"key":"1622_CR44","unstructured":"2025 U.S. organ and tissue transplants: Estimated costs and utilization, emerging issues, and solutions [Internet]. [cited 2026 Mar 9]. https:\/\/www.milliman.com\/en\/insight\/2025-us-organ-and-tissue-transplants-costs-utilization. Accessed 9 Mar 2026"},{"key":"1622_CR45","unstructured":"Kumar R, Viswanath O, Saadabadi A. Buprenorphine. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Aug 8]. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459126\/. Accessed 8 Aug 2025"},{"key":"1622_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0216205","volume":"14","author":"EH Teshale","year":"2019","unstructured":"Teshale EH, Asher A, Aslam MV, Augustine R, Duncan E, Rose-Wood A, et al. Estimated cost of comprehensive syringe service program in the United States. PLoS One. 2019;14:e0216205. https:\/\/doi.org\/10.1371\/journal.pone.0216205.","journal-title":"PLoS One"},{"key":"1622_CR47","doi-asserted-by":"publisher","unstructured":"Institute for Health Metrics and Evaluation. Global Burden of Disease Study 2021 (GBD 2021) United States Burden of Disease Forecasts 2022-2050 [Internet]. Institute for Health Metrics and Evaluation; 2024 [cited 2025 Aug 8]. https:\/\/doi.org\/10.6069\/82E4-E232","DOI":"10.6069\/82E4-E232"},{"key":"1622_CR48","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/cid\/ciac543","volume":"76","author":"H Bradley","year":"2023","unstructured":"Bradley H, Hall EW, Asher A, Furukawa NW, Jones CM, Shealey J, et al. Estimated number of people who inject drugs in the United States. Clin Infect Dis. 2023;76:96\u2013102. https:\/\/doi.org\/10.1093\/cid\/ciac543.","journal-title":"Clin Infect Dis"},{"key":"1622_CR49","unstructured":"2022-teds-annual-detailed-tables."},{"key":"1622_CR50","unstructured":"NSDUH State Releases | CBHSQ Data [Internet]. [cited 2025 Aug 11]. https:\/\/www.samhsa.gov\/data\/data-we-collect\/nsduh-national-survey-drug-use-and-health\/state-releases. Accessed 11 Aug 2025."},{"key":"1622_CR51","doi-asserted-by":"publisher","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","volume":"5","author":"L Degenhardt","year":"2017","unstructured":"Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5:e1192\u2013207. https:\/\/doi.org\/10.1016\/S2214-109X(17)30375-3.","journal-title":"Lancet Glob Health"},{"key":"1622_CR52","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/hep.22375","volume":"48","author":"H Thein","year":"2008","unstructured":"Thein H, Yi Q, Dore GJ, Krahn MD. Estimation of stage\u2010specific fibrosis progression rates in chronic hepatitis C virus infection: a meta\u2010analysis and meta\u2010regression\u2020. Hepatology. 2008;48:418\u201331. https:\/\/doi.org\/10.1002\/hep.22375.","journal-title":"Hepatology"},{"key":"1622_CR53","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1002\/hep.28571","volume":"64","author":"J Chhatwal","year":"2016","unstructured":"Chhatwal J, Wang X, Ayer T, Kabiri M, Chung RT, Hur C, et al. Hepatitis C disease burden in the United States in the era of oral direct\u2010acting antivirals. Hepatology. 2016;64:1442\u201350. https:\/\/doi.org\/10.1002\/hep.28571.","journal-title":"Hepatology"},{"key":"1622_CR54","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/add.14012","volume":"113","author":"L Platt","year":"2018","unstructured":"Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, et al. Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta\u2010analysis. Addiction. 2018;113:545\u201363. https:\/\/doi.org\/10.1111\/add.14012.","journal-title":"Addiction"},{"key":"1622_CR55","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1365-2893.2005.00651.x","volume":"13","author":"JM Micallef","year":"2006","unstructured":"Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 2006;13:34\u201341. https:\/\/doi.org\/10.1111\/j.1365-2893.2005.00651.x.","journal-title":"J Viral Hepat"},{"key":"1622_CR56","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/apt.15291","volume":"50","author":"J Chhatwal","year":"2019","unstructured":"Chhatwal J, Chen Q, Bethea ED, Hur C, Spaulding AC, Kanwal F. The impact of direct\u2010acting anti\u2010virals on the hepatitis C care cascade: identifying progress and gaps towards hepatitis C elimination in the United States. Aliment Pharmacol Ther. 2019;50:66\u201374. https:\/\/doi.org\/10.1111\/apt.15291.","journal-title":"Aliment Pharmacol Ther"},{"key":"1622_CR57","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/S0167-6296(97)00004-0","volume":"16","author":"CJL Murray","year":"1997","unstructured":"Murray CJL, Acharya AK. Understanding DALYs. J Health Econ. 1997;16:703\u201330. https:\/\/doi.org\/10.1016\/S0167-6296(97)00004-0.","journal-title":"J Health Econ"},{"key":"1622_CR58","doi-asserted-by":"publisher","first-page":"e833","DOI":"10.1016\/S2214-109X(23)00162-6","volume":"11","author":"A Pichon-Riviere","year":"2023","unstructured":"Pichon-Riviere A, Drummond M, Palacios A, Garcia-Marti S, Augustovski F. Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures. Lancet Glob Health. 2023;11:e833\u201342. https:\/\/doi.org\/10.1016\/S2214-109X(23)00162-6.","journal-title":"Lancet Glob Health"},{"key":"1622_CR59","unstructured":"Health Care Expenditures per Capita by State of Residence [Internet]. KFF. [cited 2025 Aug 8]. https:\/\/www.kff.org\/other\/state-indicator\/health-spending-per-capita\/. Accessed 8 Aug 2025"},{"key":"1622_CR60","unstructured":"Real per capita GDP by state U.S. 2024 [Internet]. Statista. [cited 2025 Aug 8]. https:\/\/www.statista.com\/statistics\/248063\/per-capita-us-real-gross-domestic-product-gdp-by-state\/. Accessed 8 Aug 2025"},{"key":"1622_CR61","doi-asserted-by":"publisher","unstructured":"Kohli-Lynch CN. Probabilistic sensitivity analysis and value of information analysis. In: Bishai D, Brenzel L, Padula W, editors. Handb Appl Health Econ Vaccines [Internet]. 1st ed. Oxford University Press; 2023 [cited 2025 Sept 23]. p. 290\u2013309. https:\/\/doi.org\/10.1093\/oso\/9780192896087.003.0024","DOI":"10.1093\/oso\/9780192896087.003.0024"},{"key":"1622_CR62","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1177\/0272989X12458348","volume":"32","author":"AH Briggs","year":"2012","unstructured":"Briggs AH, Weinstein MC, Fenwick EAL, Karnon J, Sculpher MJ, Paltiel AD. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group\u20136. Med Decis Making. 2012;32:722\u201332. https:\/\/doi.org\/10.1177\/0272989X12458348.","journal-title":"Med Decis Making"},{"key":"1622_CR63","doi-asserted-by":"publisher","unstructured":"Borgonovo E. Sensitivity Analysis [Internet]. Springer International Publishing; 2017 [cited 2025 Aug 12]. https:\/\/doi.org\/10.1007\/978-3-319-52259-3","DOI":"10.1007\/978-3-319-52259-3"},{"key":"1622_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-024-11793-4","volume":"24","author":"SA Choi","year":"2024","unstructured":"Choi SA, Umashankar K, Maheswaran A, Martin MT, Lee J, Odishoo M, et al. Cost-effectiveness analysis of emergency department-based Hepatitis C screening and linkage-to-care program. BMC Health Serv Res. 2024;24:1308. https:\/\/doi.org\/10.1186\/s12913-024-11793-4.","journal-title":"BMC Health Serv Res"},{"key":"1622_CR65","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.15756","volume":"3","author":"M Tatar","year":"2020","unstructured":"Tatar M, Keeshin SW, Mailliard M, Wilson FA. Cost-effectiveness of universal and targeted Hepatitis C Virus screening in the United States. JAMA Netw Open. 2020;3:e2015756. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.15756.","journal-title":"JAMA Netw Open"},{"key":"1622_CR66","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing [Internet]. Vienna, Austria; 2024. http:\\\\r-project.org."},{"key":"1622_CR67","doi-asserted-by":"publisher","unstructured":"Soetaert K, Petzoldt T, Setzer RW. Solving Differential Equations in R\u202f: Package deSolve. J Stat Softw [Internet]. 2010 [cited 2025 Aug 8];33. https:\/\/doi.org\/10.18637\/jss.v033.i09","DOI":"10.18637\/jss.v033.i09"},{"key":"1622_CR68","doi-asserted-by":"publisher","DOI":"10.21105\/joss.01686","volume":"4","author":"H Wickham","year":"2019","unstructured":"Wickham H, Averick M, Bryan J, Chang W, McGowan L, Fran\u00e7ois R, et al. Welcome to the Tidyverse. J Open Sour Softw. 2019;4:1686. https:\/\/doi.org\/10.21105\/joss.01686.","journal-title":"J Open Sour Softw"},{"key":"1622_CR69","doi-asserted-by":"publisher","unstructured":"Goueguel CL. ConfidenceEllipse: computation of 2D and 3D elliptical joint confidence regions [Internet]. 2024 [cited 2025 Aug 8]. p. 1.1.0. https:\/\/doi.org\/10.32614\/CRAN.package.ConfidenceEllipse","DOI":"10.32614\/CRAN.package.ConfidenceEllipse"},{"key":"1622_CR70","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jhep.2016.02.007","volume":"65","author":"NK Martin","year":"2016","unstructured":"Martin NK, Vickerman P, Dore GJ, Grebely J, Miners A, Cairns J, et al. Prioritization of HCV treatment in the direct-acting antiviral era: an economic evaluation. J Hepatol. 2016;65:17\u201325. https:\/\/doi.org\/10.1016\/j.jhep.2016.02.007.","journal-title":"J Hepatol"},{"key":"1622_CR71","unstructured":"Mavyret patent expiration [Internet]. [cited 2025 Aug 11]. https:\/\/pharsight.greyb.com\/drug\/mavyret-patent-expiration. Accessed 11 Aug 2025"},{"key":"1622_CR72","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1097\/JOM.0000000000002612","volume":"64","author":"JR Morgan","year":"2022","unstructured":"Morgan JR, Murphy SM, Assoumou SA, Linas BP. Estimating absenteeism related to nonalcohol substance use in a US national cohort of full-time employees. J Occup Environ Med. 2022;64:899\u2013904. https:\/\/doi.org\/10.1097\/JOM.0000000000002612.","journal-title":"J Occup Environ Med"},{"key":"1622_CR73","doi-asserted-by":"publisher","first-page":"S118","DOI":"10.1016\/j.amepre.2021.05.044","volume":"61","author":"D Broz","year":"2021","unstructured":"Broz D, Carnes N, Chapin-Bardales J, Des Jarlais DC, Handanagic S, Jones CM, et al. Syringe services programs\u2019 role in ending the HIV epidemic in the U.S.: why we cannot do it without them. Am J Prev Med. 2021;61:S118-29. https:\/\/doi.org\/10.1016\/j.amepre.2021.05.044.","journal-title":"Am J Prev Med"},{"key":"1622_CR74","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1089\/wound.2020.1243","volume":"10","author":"DP Sanchez","year":"2021","unstructured":"Sanchez DP, Tookes H, Pastar I, Lev-Tov H. Wounds and skin and soft tissue infections in people who inject drugs and the utility of syringe service programs in their management. Adv Wound Care. 2021;10:571\u201382. https:\/\/doi.org\/10.1089\/wound.2020.1243.","journal-title":"Adv Wound Care"},{"key":"1622_CR75","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1111\/j.1360-0443.2008.02465.x","volume":"104","author":"DC Des Jarlais","year":"2009","unstructured":"Des Jarlais DC, McKnight C, Goldblatt C, Purchase D. Doing harm reduction better: syringe exchange in the United States. Addiction. 2009;104:1441\u20136. https:\/\/doi.org\/10.1111\/j.1360-0443.2008.02465.x.","journal-title":"Addiction"},{"key":"1622_CR76","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1111\/add.14978","volume":"115","author":"Z Ward","year":"2020","unstructured":"Ward Z, Reynolds R, Campbell L, Martin NK, Harrison G, Irving W, et al. Cost\u2010effectiveness of the HepCATT intervention in specialist drug clinics to improve case\u2010finding and engagement with HCV treatment for people who inject drugs in England. Addiction. 2020;115:1509\u201321. https:\/\/doi.org\/10.1111\/add.14978.","journal-title":"Addiction"},{"key":"1622_CR77","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3350\/cmh.2021.0236","volume":"28","author":"H-L Kim","year":"2022","unstructured":"Kim H-L, Kim K-A, Choi GH, Jang ES, Ki M, Choi HY, et al. A cost-effectiveness study of universal screening for Hepatitis C virus infection in South Korea: a societal perspective. Clin Mol Hepatol. 2022;28:91\u2013104. https:\/\/doi.org\/10.3350\/cmh.2021.0236.","journal-title":"Clin Mol Hepatol"},{"key":"1622_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2021.100129","volume":"10","author":"N Scott","year":"2021","unstructured":"Scott N, Win TM, Tidhar T, Htay H, Draper B, Aung PTZ, et al. Hepatitis C elimination in Myanmar: modelling the impact, cost, cost-effectiveness and economic benefits. Lancet Reg Health West Pac. 2021;10:100129. https:\/\/doi.org\/10.1016\/j.lanwpc.2021.100129.","journal-title":"Lancet Reg Health West Pac"},{"key":"1622_CR79","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1177\/0272989X15598528","volume":"36","author":"JL Juusola","year":"2016","unstructured":"Juusola JL, Brandeau ML. HIV treatment and prevention: a simple model to determine optimal investment. Med Decis Mak. 2016;36:391\u2013409. https:\/\/doi.org\/10.1177\/0272989X15598528.","journal-title":"Med Decis Mak"},{"key":"1622_CR80","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1093\/cid\/ciz696","volume":"70","author":"C Graf","year":"2020","unstructured":"Graf C, M\u00fccke MM, Dultz G, Peiffer K-H, Kubesch A, Ingiliz P, et al. Efficacy of direct-acting antivirals for chronic Hepatitis C virus infection in people who inject drugs or receive opioid substitution therapy: a systematic review and meta-analysis. Clin Infect Dis. 2020;70:2355\u201365. https:\/\/doi.org\/10.1093\/cid\/ciz696.","journal-title":"Clin Infect Dis"},{"key":"1622_CR81","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12954-021-00519-y","volume":"18","author":"S Frankova","year":"2021","unstructured":"Frankova S, Jandova Z, Jinochova G, Kreidlova M, Merta D, Sperl J. Therapy of chronic hepatitis C in people who inject drugs: focus on adherence. Harm Reduct J. 2021;18:69. https:\/\/doi.org\/10.1186\/s12954-021-00519-y.","journal-title":"Harm Reduct J"},{"key":"1622_CR82","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.jhep.2016.01.001","volume":"64","author":"H Midgard","year":"2016","unstructured":"Midgard H, Bj\u00f8ro B, M\u00e6land A, Konopski Z, Kileng H, Dam\u00e5s JK, et al. Hepatitis C reinfection after sustained virological response. J Hepatol. 2016;64:1020\u20136. https:\/\/doi.org\/10.1016\/j.jhep.2016.01.001.","journal-title":"J Hepatol"},{"key":"1622_CR83","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.drugpo.2017.05.040","volume":"47","author":"H Midgard","year":"2017","unstructured":"Midgard H, Hajarizadeh B, Cunningham EB, Conway B, Backmund M, Bruggmann P, et al. Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study. Int J Drug Policy. 2017;47:230\u20138. https:\/\/doi.org\/10.1016\/j.drugpo.2017.05.040.","journal-title":"Int J Drug Policy"},{"key":"1622_CR84","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.45424","volume":"5","author":"VH Nguyen","year":"2022","unstructured":"Nguyen VH, Kam L, Yeo YH, Huang DQ, Henry L, Cheung R, et al. Characteristics and treatment rate of patients with Hepatitis C virus infection in the direct-acting antiviral era and during the COVID-19 pandemic in the United States. JAMA Netw Open. 2022;5:e2245424. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.45424.","journal-title":"JAMA Netw Open"},{"key":"1622_CR85","doi-asserted-by":"publisher","first-page":"S420","DOI":"10.1093\/infdis\/jiaa337","volume":"222","author":"R Lewis","year":"2020","unstructured":"Lewis R, Baugher AR, Finlayson T, Wejnert C, Sionean C, National HIV Behavioral Surveillance (NHBS) Study Group. Healthcare access and utilization among persons who inject drugs in Medicaid expansion and nonexpansion states: 22 United States cities, 2018. J Infect Dis. 2020;222:S420-8. https:\/\/doi.org\/10.1093\/infdis\/jiaa337.","journal-title":"J Infect Dis"},{"key":"1622_CR86","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/add.16383","volume":"119","author":"H Cooper","year":"2024","unstructured":"Cooper H, Beane S, Yarbrough C, Haard\u00f6rfer R, Ibragimov U, Haley D, et al. Association of Medicaid expansion with health insurance, unmet need for medical care and substance use disorder treatment among people who inject drugs in 13 US states. Addiction. 2024;119:582\u201392. https:\/\/doi.org\/10.1111\/add.16383.","journal-title":"Addiction"},{"key":"1622_CR87","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","volume":"35","author":"C Timko","year":"2016","unstructured":"Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C. Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Dis. 2016;35:22\u201335. https:\/\/doi.org\/10.1080\/10550887.2016.1100960.","journal-title":"J Addict Dis"},{"key":"1622_CR88","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c3172","volume":"341","author":"J Kimber","year":"2010","unstructured":"Kimber J, Copeland L, Hickman M, Macleod J, McKenzie J, De Angelis D, et al. Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment. BMJ. 2010;341:c3172\u2013c3172. https:\/\/doi.org\/10.1136\/bmj.c3172.","journal-title":"BMJ"},{"key":"1622_CR89","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0324088","volume":"20","author":"LS Miller","year":"2025","unstructured":"Miller LS, Rao A, Tunnell K, Wang YF, Parsons R, McLendon K, et al. Independent assessment of a point of care HCV RNA test by laboratory analytical testing and a prospective field study in the U.S. PLoS One. 2025;20:e0324088. https:\/\/doi.org\/10.1371\/journal.pone.0324088.","journal-title":"PLoS One"},{"key":"1622_CR90","unstructured":"Sen. Hassan MW [D-N. S.445 - 117th Congress (2021-2022): Mainstreaming Addiction Treatment Act of 2021 [Internet]. 2021 [cited 2025 Aug 13]. https:\/\/www.congress.gov\/bill\/117th-congress\/senate-bill\/445. Accessed 13 Aug 2025"},{"key":"1622_CR91","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-023-09773-1","volume":"23","author":"JJ Chiosi","year":"2023","unstructured":"Chiosi JJ, Mueller PP, Chhatwal J, Ciaranello AL. A multimorbidity model for estimating health outcomes from the syndemic of injection drug use and associated infections in the United States. BMC Health Serv Res. 2023;23:760. https:\/\/doi.org\/10.1186\/s12913-023-09773-1.","journal-title":"BMC Health Serv Res"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01622-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-026-01622-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01622-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T19:02:49Z","timestamp":1787425369000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-026-01622-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":91,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1622"],"URL":"https:\/\/doi.org\/10.1007\/s40273-026-01622-3","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"29 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ST is currently employed by the Kansas Department of Health and Environment. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Kansas Department of Health and Environment.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data needed to evaluate the conclusions in the paper are present in the paper and supplementary materials.","order":2,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":".","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ST: Study conception and design, development of the economic model, data analysis and interpretation, drafting of the manuscript. FC: Study conception and design, data analysis and interpretation, critical revision of the paper for intellectual content, supervision.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}